Colonization and infection with vancomycin-resistant enterococcus among patients with cancer

Madonna J. Matar; Jeffrey Tarrand; Issam Raad; Kenneth V.I. Rolston

doi:10.1016/j.ajic.2006.04.205

Colonization and infection with vancomycin-resistant enterococcus among patients with cancer

Madonna J. Matar, Jeffrey Tarrand, Issam Raad, Kenneth V.I. Rolston

Research output: Contribution to journal › Article › peer-review

88 Scopus citations

Abstract

Vancomycin-resistant enterococci (VRE) cause substantial morbidity and mortality in immune-suppressed patients. In a retrospective review, VRE fecal colonization was documented in 4.7% (99 of 2115) of patients screened, with 5.4% of patients with leukemia, 4.9% of hematopoietic stem cell transplantation recipients, and 2.2% of patients with lymphoma being colonized. Among the 99 patients with VRE colonization, 29 (29.29%) developed bacteremia, and there were 32 episodes of VRE infection at other sites. The rate of VRE bacteremia in solid tumor patients (0.12%) was significantly lower (P ≤ .0001). VRE colonization had a negative predictive value of 99.9% and a positive predictive value of 29.3% for the development of VRE bacteremia and might help identify a high-risk subset of patients that might benefit from preemptive VRE therapy during episodes of neutropenic fever.

Original language	English (US)
Pages (from-to)	534-536
Number of pages	3
Journal	American Journal of Infection Control
Volume	34
Issue number	8
DOIs	https://doi.org/10.1016/j.ajic.2006.04.205
State	Published - Oct 2006

ASJC Scopus subject areas

Epidemiology
Health Policy
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.ajic.2006.04.205

Cite this

@article{7d0ff847fdcb40179f7e71401040d3b4,

title = "Colonization and infection with vancomycin-resistant enterococcus among patients with cancer",

abstract = "Vancomycin-resistant enterococci (VRE) cause substantial morbidity and mortality in immune-suppressed patients. In a retrospective review, VRE fecal colonization was documented in 4.7% (99 of 2115) of patients screened, with 5.4% of patients with leukemia, 4.9% of hematopoietic stem cell transplantation recipients, and 2.2% of patients with lymphoma being colonized. Among the 99 patients with VRE colonization, 29 (29.29%) developed bacteremia, and there were 32 episodes of VRE infection at other sites. The rate of VRE bacteremia in solid tumor patients (0.12%) was significantly lower (P ≤ .0001). VRE colonization had a negative predictive value of 99.9% and a positive predictive value of 29.3% for the development of VRE bacteremia and might help identify a high-risk subset of patients that might benefit from preemptive VRE therapy during episodes of neutropenic fever.",

author = "Matar, {Madonna J.} and Jeffrey Tarrand and Issam Raad and Rolston, {Kenneth V.I.}",

year = "2006",

month = oct,

doi = "10.1016/j.ajic.2006.04.205",

language = "English (US)",

volume = "34",

pages = "534--536",

journal = "American Journal of Infection Control",

issn = "0196-6553",

publisher = "Mosby Inc.",

number = "8",

}

TY - JOUR

T1 - Colonization and infection with vancomycin-resistant enterococcus among patients with cancer

AU - Matar, Madonna J.

AU - Tarrand, Jeffrey

AU - Raad, Issam

AU - Rolston, Kenneth V.I.

PY - 2006/10

Y1 - 2006/10

N2 - Vancomycin-resistant enterococci (VRE) cause substantial morbidity and mortality in immune-suppressed patients. In a retrospective review, VRE fecal colonization was documented in 4.7% (99 of 2115) of patients screened, with 5.4% of patients with leukemia, 4.9% of hematopoietic stem cell transplantation recipients, and 2.2% of patients with lymphoma being colonized. Among the 99 patients with VRE colonization, 29 (29.29%) developed bacteremia, and there were 32 episodes of VRE infection at other sites. The rate of VRE bacteremia in solid tumor patients (0.12%) was significantly lower (P ≤ .0001). VRE colonization had a negative predictive value of 99.9% and a positive predictive value of 29.3% for the development of VRE bacteremia and might help identify a high-risk subset of patients that might benefit from preemptive VRE therapy during episodes of neutropenic fever.

AB - Vancomycin-resistant enterococci (VRE) cause substantial morbidity and mortality in immune-suppressed patients. In a retrospective review, VRE fecal colonization was documented in 4.7% (99 of 2115) of patients screened, with 5.4% of patients with leukemia, 4.9% of hematopoietic stem cell transplantation recipients, and 2.2% of patients with lymphoma being colonized. Among the 99 patients with VRE colonization, 29 (29.29%) developed bacteremia, and there were 32 episodes of VRE infection at other sites. The rate of VRE bacteremia in solid tumor patients (0.12%) was significantly lower (P ≤ .0001). VRE colonization had a negative predictive value of 99.9% and a positive predictive value of 29.3% for the development of VRE bacteremia and might help identify a high-risk subset of patients that might benefit from preemptive VRE therapy during episodes of neutropenic fever.

UR - http://www.scopus.com/inward/record.url?scp=33749266018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749266018&partnerID=8YFLogxK

U2 - 10.1016/j.ajic.2006.04.205

DO - 10.1016/j.ajic.2006.04.205

M3 - Article

C2 - 17015161

AN - SCOPUS:33749266018

SN - 0196-6553

VL - 34

SP - 534

EP - 536

JO - American Journal of Infection Control

JF - American Journal of Infection Control

IS - 8

ER -

Colonization and infection with vancomycin-resistant enterococcus among patients with cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this